JNJ Continues to Grow AD Pipeline With New Licensing Agreement
Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical. Johnson & Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723. Kaken will retain the commercialization rights in […]